Certa Therapeutics Expands GPR68 Platform with OccuRx Acquisition

Certa Therapeutics, a Melbourne-based biotechnology company known for its pioneering work on treatments for fibrotic diseases, has announced its acquisition of OccuRx, another Melbourne-based biotech focused on similar therapeutic areas. The unification under Certa has fortified a robust pipeline of drug candidates, including those already in Phase 2 and Phase 1 clinical trials, specifically targeting fibrosis through the G protein-coupled receptor GPR68, which is described as a 'master switch' of fibrosis. The merger consolidates assets originally developed by Professor Darren Kelly, the founder of both companies, enhancing their operational focus in developing precision therapies for fibrotic diseases characterized by significant unmet medical need. Certa's lead therapy, Asengeprast (FT011), designed for systemic sclerosis, has been granted Orphan Drug Designation and Fast Track status by the FDA. Post-acquisition, Certa's resources will also include OCX063, a candidate for treating focal segmental glomerulosclerosis, alongside second-generation compounds for chronic kidney disease and a lineup of third-generation GPR68 antagonists aimed at various fibrotic conditions. The acquisition is supported by prominent investors such as Brandon Capital Partners and Uniseed, with a cumulative capitalization achieving $30 million over the last six years. Certa plans to continue advancing its clinical programs and expand operations with a Series B funding round.